{"title":"更正：\"通过 miR-451a/HK2 轴抑制有氧糖酵解，敲除 lncRNA DLGAP1-AS2 可抑制骨肉瘤的发展\"。","authors":"","doi":"10.1111/cas.16403","DOIUrl":null,"url":null,"abstract":"<p>Zheng C, Li R, Zheng S, Fang H, Xu M, Zhong L. The knockdown of lncRNA DLGAP1-AS2 suppresses osteosarcoma progression by inhibiting aerobic glycolysis via the miR-451a/HK2 axis. <i>Cancer Sci</i> 2023;114(12):4747–4762.</p><p>We used the incorrect U6 prime sequence in this study. For the validity and rigorousness of research results, we redesigned the correct U6 primer sequence and repeated the related experiments (Figures 4, 5 and 6). Please kindly change the data of Figures 4D, 4E, and 6F, as well as U6 prime sequence U6 (F: 5′-CTCGCTTCGGCAGCACAT-3′, R: 5′-TTTGCGTGTCATCCTTGCG-3′) in manuscript.</p><p>We apologize for this error.</p>","PeriodicalId":9580,"journal":{"name":"Cancer Science","volume":"116 2","pages":"564"},"PeriodicalIF":4.5000,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11786302/pdf/","citationCount":"0","resultStr":"{\"title\":\"Correction to “The knockdown of lncRNA DLGAP1-AS2 suppresses osteosarcoma progression by inhibiting aerobic glycolysis via the miR-451a/HK2 axis”\",\"authors\":\"\",\"doi\":\"10.1111/cas.16403\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Zheng C, Li R, Zheng S, Fang H, Xu M, Zhong L. The knockdown of lncRNA DLGAP1-AS2 suppresses osteosarcoma progression by inhibiting aerobic glycolysis via the miR-451a/HK2 axis. <i>Cancer Sci</i> 2023;114(12):4747–4762.</p><p>We used the incorrect U6 prime sequence in this study. For the validity and rigorousness of research results, we redesigned the correct U6 primer sequence and repeated the related experiments (Figures 4, 5 and 6). Please kindly change the data of Figures 4D, 4E, and 6F, as well as U6 prime sequence U6 (F: 5′-CTCGCTTCGGCAGCACAT-3′, R: 5′-TTTGCGTGTCATCCTTGCG-3′) in manuscript.</p><p>We apologize for this error.</p>\",\"PeriodicalId\":9580,\"journal\":{\"name\":\"Cancer Science\",\"volume\":\"116 2\",\"pages\":\"564\"},\"PeriodicalIF\":4.5000,\"publicationDate\":\"2024-11-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11786302/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Science\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/cas.16403\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Science","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/cas.16403","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
Correction to “The knockdown of lncRNA DLGAP1-AS2 suppresses osteosarcoma progression by inhibiting aerobic glycolysis via the miR-451a/HK2 axis”
Zheng C, Li R, Zheng S, Fang H, Xu M, Zhong L. The knockdown of lncRNA DLGAP1-AS2 suppresses osteosarcoma progression by inhibiting aerobic glycolysis via the miR-451a/HK2 axis. Cancer Sci 2023;114(12):4747–4762.
We used the incorrect U6 prime sequence in this study. For the validity and rigorousness of research results, we redesigned the correct U6 primer sequence and repeated the related experiments (Figures 4, 5 and 6). Please kindly change the data of Figures 4D, 4E, and 6F, as well as U6 prime sequence U6 (F: 5′-CTCGCTTCGGCAGCACAT-3′, R: 5′-TTTGCGTGTCATCCTTGCG-3′) in manuscript.
期刊介绍：
Cancer Science (formerly Japanese Journal of Cancer Research) is a monthly publication of the Japanese Cancer Association. First published in 1907, the Journal continues to publish original articles, editorials, and letters to the editor, describing original research in the fields of basic, translational and clinical cancer research. The Journal also accepts reports and case reports.
Cancer Science aims to present highly significant and timely findings that have a significant clinical impact on oncologists or that may alter the disease concept of a tumor. The Journal will not publish case reports that describe a rare tumor or condition without new findings to be added to previous reports; combination of different tumors without new suggestive findings for oncological research; remarkable effect of already known treatments without suggestive data to explain the exceptional result. Review articles may also be published.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
